review of literature on clinical pancreatology - The Pancreapedia

531. Turrini O, Viret F, Moureau-Zabotto L, Guiramand J, Moutardier V, Lelong B, de Chaisemartin C,Giovannini M, Delpero JR. Neoadjuvant 5-fluorouracil-cisplatin chemoradiation effect on survival inpatients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience.Oncology 2009; 76: 413-9.532. Moody JS, Sawrie SM, Kozak KR, Plastaras JP, Howard G, Bonner JA. Adjuvant radiotherapy forpancreatic cancer is associated with a survival benefit primarily in stage IIB patients. J Gastroenterol2009; 44: 84-91.533. Davila JA, Chiao EY, Hasche JC, Petersen NJ, McGlynn KA, Shaib YH. Utilization anddeterminants <strong>of</strong> adjuvant therapy among older patients who receive curative surgery for pancreaticcancer. Pancreas 2009; 38: e18-25.534. Tawada K, Yamaguchi T, Kobayashi A, Ishihara T, Sudo K, Nakamura K, Hara T, Denda T,Matsuyama M, Yokosuka O. Changes in tumor vascularity depicted by contrast-enhancedultrasonography as a predictor <strong>of</strong> chemotherapeutic effect in patients with unresectable pancreaticcancer. Pancreas 2009; 38: 30-5.535. Tsumura T, Matsuo H, Maruo T, Kawakami H, Hatano K, Saito S, Nishijima N, Nakatsuji M, IkedaA, Nishikawa H, Kita R, Okabe Y, Kimura T, Amitani R, Osaki Y. Seven cases <strong>of</strong> gemcitabine-inducedlung injury during treatment for pancreatic or biliary tract cancers. Gan To Kagaku Ryoho 2009; 36:785-8 (in Japanese).536. Ishibashi Y, Ito Y. A case <strong>of</strong> drug induced interstitial pneumonitis after gemcitabine treatment forpancreatic carcinoma. Gan To Kagaku Ryoho 2009; 36: 651-3 (in Japanese).537. Recchia F, Sica G, Candeloro G, Bisegna R, Bratta M, Bonfili P, Necozione S, Tombolini V, ReaS. Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: amulticenter phase II study. Pancreas 2009; 38: e163-8.538. Fukada I, Ikeda H, Yamaguchi K, Okabe M, Tsuruta A, Morimoto Y, Kawamoto K, Sano K, PakuT, Imai S, Yoshida Y, Ito T, Ogasahara K. A case <strong>of</strong> recurrent pancreatic cancer with lung metastasisresponding to S-1 combined gemcitabine chemotherapy. Gan To Kagaku Ryoho 2009; 36: 1733-6 (inJapanese).539. Sasajima J, Tanno S, Koizumi K, Nakano Y, Habiro A, Chiba A, Fujii T, Sugiyama Y, NakamuraK, Nishikawa T, Mizukami Y, Okumura T, Kohgo Y. Gemcitabine in combination with S-1 or UFT inpatients with advanced pancreatic cancer Gan To Kagaku Ryoho 2009; 36: 1657-61 (in Japanese).540. Neri B, Cipriani G, Grifoni R, Molinara E, Pantaleo P, Rangan S, Vannini A, Tonelli P, Valeri A,Pantalone D, Taddei A, Bechi P. Gemcitabine plus irinotecan as first-line weekly therapy in locallyadvanced and/or metastatic pancreatic cancer. Oncol Res 2009; 17: 559-64.541. Galloway NR, Aspe JR, Sellers C, Wall NR. Enhanced antitumor effect <strong>of</strong> combined gemcitabineand proton radiation in the treatment <strong>of</strong> pancreatic cancer. Pancreatology 2009; 9: 782-90.542. Graeser R, Bornmann C, Esser N, Ziroli V, Jantscheff P, Unger C, Hopt UT, Schaechtele C, vonDobschuetz E, Massing U. Antimetastatic effects <strong>of</strong> liposomal gemcitabine and empty liposomes in anorthotopic mouse model <strong>of</strong> pancreatic cancer. Pancreas 2009; 38: 330-7.543. Niki T, Soejima T, Yoshikawa T, Yamamoto Y, Fujii O, Ohta Y, Tsuda M, Horita K, Tsujino K,Hirohata S, Fujino Y, Nishisaki H. 5-FU based chemoradiotherapy for unresectable locally advancedpancreatic cancer. Gan To Kagaku Ryoho 2009; 36: 63-9 (in Japanese).544. Novarino A, Satolli MA, Chiappino I, Giacobino A, Bellone G, Rahimi F, Milanesi E, Bertetto O,Ciuffreda L. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advancedpancreatic cancer. Am J Clin Oncol 2009; 32: 44-8.